Scientists probe how new cancer drug battles tumors
NCT ID NCT04294628
Summary
This is an early, small study to understand how the drug DS-8201a works in the body of patients with advanced HER2-positive cancers. Researchers are giving the drug to 62 patients and taking small tumor samples before and after treatment to see how it affects cancer cells and the immune system. The main goal is to learn about the drug's biological effects, not primarily to measure how well it shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.